Emcure Pharmaceuticals Limited (EMCURE) reports Q1 FY27 results with revenue up 22.8% and PAT surging 36.2%.
Emcure Pharmaceuticals Limited (EMCURE) expands Poviztra® for MASH treatment, addressing unmet medical needs for metabolic dysfunction-associated steatohepat.
Emcure Pharmaceuticals Limited consolidates Gennova ownership, sharpens focus on biologics; Samit Mehta leads next phase of growth.
Emcure Pharmaceuticals Limited (NSE: EMCURE) stock price moves up 5% intraday to ₹1884.0, clearing its 6M resistance trendline in a breakout move.
Emcure Pharmaceuticals Limited (EMCURE) reports strong FY26 results with revenue up 16.6% and margin expansion, driven by robust international performance.
Emcure Pharmaceuticals Limited shows robust Q4 FY26 results with 16.6% revenue growth and strategic portfolio expansion.
Emcure Pharmaceuticals Limited reports strong Q4 FY26 results with 16.7% revenue growth and 19.7% EBITDA margin.